MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

MacroGenics reported third quarter 2026 total revenues of $18.7 million, against $53.0 million in the same quarter of 2025. The company attributes the decline primarily to $50.0 million of milestone revenue recognized in 2025 under the Provention (Sanofi) Asset Purchase Agreement, compared with $10.0 million recognized in 2026 from the Gilead option exercise. Royalty revenue was $8,582 thousand against $3,333 thousand a year earlier, and the company describes a $5.3 million increase in ZYNYZ royalty revenue. Collaborative and other agreements revenue was $10,085 thousand against $49,670 thousand. For the nine months, total revenues were $58,220 thousand against $66,915 thousand, with royalty revenue at $22,078 thousand against $5,087 thousand.

Operating expenses declined. Research and development expenses were $30.6 million against $32.7 million, and the company links the decrease to lower lorigerlimab, vobramitamab duocarmazine, MGC030 manufacturing and IND-enabling costs, partly offset by higher MGC026, MGC028, MGC030 clinical and next-generation T-cell engager costs. General and administrative expenses were $8.4 million against $9.9 million, which the company ascribes to lower personnel-related costs including stock-based compensation. Total costs and expenses were $38,970 thousand against $42,614 thousand. Income from operations swung to an operating loss of $(20,303) thousand from income of $10,389 thousand a year earlier.

Below the operating line, the net result was a loss of $(20,076) thousand, or $(0.32) per diluted share, against net income of $16,822 thousand, or $0.27 per diluted share. Net income from discontinued operations of $1,399 thousand (against $8,247 thousand) reflects the CDMO business that was sold, and the filing reports the cash received from that sale: $119.6 million from Bora. Interest and other expense for the nine months was $(13,369) thousand against $(4,236) thousand, and the nine-month results include a $(52,762) thousand loss on extinguishment of royalty monetization liability, which has no prior-year amount printed. All figures in the release are GAAP; the filing contains no non-GAAP measures.

Cash, cash equivalents and marketable securities rose to $287.7 million at September 30, 2026 from $189.9 million at December 31, 2025, with the increase reflecting the Bora, Sanofi and Gilead receipts the company lists for the quarter. Total stockholders' equity fell to $25,151 thousand from $55,591 thousand over the same period, and the filing does not explain that decline in the balance sheet data. The company reiterates cash runway through 2028, based on the cash balance plus projected partner payments. No guidance on revenue, margin or expenses was given, and no prior outlook was provided for comparison.

The pipeline milestones are the main forward items. MGC028 is planned for a randomized two-dose evaluation by year end 2026, with an interim update in the first half of 2027. MGC026 enrollment of the 40-patient SCCHN cohort is planned by year end 2026, with data in mid-2027, and the company says it is reviewing its development and collaboration strategy for that molecule given the evolving competitive landscape. Lorigerlimab enrollment of 20 CCGC patients at 3 mg/kg Q3W is expected by year end 2026. The reader should weigh the sharp revenue decline and the return to operating and net losses against the cash balance, the runway statement and the 2027 milestone schedule.